Saturday, July 5, 2025
  • Login
Euro Times
No Result
View All Result
  • Home
  • Finance
  • Business
  • World
  • Politics
  • Markets
  • Stock Market
  • Cryptocurrency
  • Investing
  • Health
  • Technology
  • Home
  • Finance
  • Business
  • World
  • Politics
  • Markets
  • Stock Market
  • Cryptocurrency
  • Investing
  • Health
  • Technology
Euro Times
No Result
View All Result

Junshi, Rxilient form JV for cancer drug toripalimab in Southeast Asia

by Euro Times
March 29, 2023
in Business
Reading Time: 2 mins read
A A
0
Home Business
Share on FacebookShare on Twitter


PeopleImages

Shanghai Junshi Biosciences (OTCPK:SHJBF) is collaborating with Rxilient Biotech to develop and sell cancer drug toripalimab through a joint venture, Excellmab, in nine Southeast Asian nations.

Under the agreement, Rxilient will subscribe to the newly issued shares of Excellmab for ~$5M and Junshi will pay for the subscription amount under a shareholders’ agreement by granting Excellmab rights under a licensing agreement.

After issuance, Rxilient will own 60% of Excellmab while Junshi will own the remaining 40%.

Excellmab will be responsible for development, medical affairs, production of finished products, and sale of the products within the territory, which consists of nine Southeast Asian nations, including Thailand, Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, the Philippines, and Vietnam.

Excellmab will also get a right of first negotiation for the commercialization of four other products under research as under the license agreement in the cooperation territory. As per progress of toripalimab’s research and development and other projects, Junshi may receive milestone payment of up to ~$4.52M, plus some royalties on net sales.

Junshi has a licensing agreement with London-based Hikma Pharmaceuticals (OTCPK:HKMPF) (OTCPK:HKMPY) for the anti-PD-1 monoclonal antibody toripalimab in the Middle East and North Africa (MENA).

Toripalimab is currently under review in the U.S. to treat for nasopharyngeal carcinoma. The FDA was expected to make decision on the Coherus BioSciences’ (CHRS) biologics license application (BLA) by Dec. 23, 2022. However the agency was not able to conduct a site inspection of Junshi’s manufacturing facility in China.



Source link

Tags: AsiaCancerdrugformJunshiRxilientsoutheasttoripalimab
Previous Post

Dow Jones Futures Rise: Micron Says Sales Growth ‘Close’; LULU Stock Jumps On Earnings

Next Post

Qualys: A Cybersecurity Gem Flying Under The Radar (NASDAQ:QLYS)

Related Posts

What Moved Markets This Week

What Moved Markets This Week

by Wall Street Breakfast
July 5, 2025
0

Looking for Alpha's Calls Of The Week NextEra Power (NEE) Turns Headwinds Into Strategic Leverage.BST: Engaging Magnificent 7-Heavy CEF With...

Crude oil prices may rebound as supply tightens and geopolitical tensions ease, say experts

Crude oil prices may rebound as supply tightens and geopolitical tensions ease, say experts

by zee business
July 5, 2025
0

Crude oil costs may even see a restoration within the close to time period as constructive indicators emerge from the...

What Women Want And Do Not Want In 2025

What Women Want And Do Not Want In 2025

by Khushi Maheshwari
July 5, 2025
0

Gone are the times, hopefully, when harassing a girl on a shifting prepare was seen as 'peak romance'. The 'unhealthy...

Luma Fertility raises  mn seed funding led by Peak XV’s Surge

Luma Fertility raises $4 mn seed funding led by Peak XV’s Surge

by Euro Times
July 5, 2025
0

The funding will help development past Mumbai over the subsequent two years, tapping into India’s quickly rising fertility providers market....

Microsoft shuts down Pakistan operations after 25 years, claims founding CEO; Ex-Pak President calls it a troubling sign for economy

Microsoft shuts down Pakistan operations after 25 years, claims founding CEO; Ex-Pak President calls it a troubling sign for economy

by Euro Times
July 4, 2025
0

Microsoft has formally exited Pakistan after 25 years of operations, based on the CEO who launched the tech large’s presence...

Buy 3 IDEAL Dividend Kings Of 25 ‘Safer’ In July’s 55

Buy 3 IDEAL Dividend Kings Of 25 ‘Safer’ In July’s 55

by Fredrik Arnold
July 4, 2025
0

This text was written byComply withFredrik Arnold is a retired high quality service analyst sharing funding concepts with a major...

Next Post
Qualys: A Cybersecurity Gem Flying Under The Radar (NASDAQ:QLYS)

Qualys: A Cybersecurity Gem Flying Under The Radar (NASDAQ:QLYS)

Photos: Kids Capture Their Family Vacation in NYC, Bangkok, Rome, Paris and Washington, D.C.

Photos: Kids Capture Their Family Vacation in NYC, Bangkok, Rome, Paris and Washington, D.C.

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Kenyan president plans to build huge church at his official residence

Kenyan president plans to build huge church at his official residence

July 5, 2025
MDLZ Quantitative Stock Analysis | Nasdaq

MDLZ Quantitative Stock Analysis | Nasdaq

July 5, 2025
DeFi Is outpacing Bitcoin’s maximalist mindset

DeFi Is outpacing Bitcoin’s maximalist mindset

July 5, 2025
Why Microsoft installed a ‘secret’ update on some Windows 10 and 11 PCs

Why Microsoft installed a ‘secret’ update on some Windows 10 and 11 PCs

July 5, 2025
Beatbot AquaSense 2 Ultra robotic pool cleaner now 20% off!

Beatbot AquaSense 2 Ultra robotic pool cleaner now 20% off!

July 5, 2025
5 Stocks I’m Buying As The ‘Big Beautiful Bill’ Pushes The Market To New Highs

5 Stocks I’m Buying As The ‘Big Beautiful Bill’ Pushes The Market To New Highs

July 5, 2025
Euro Times

Get the latest news and follow the coverage of Business & Financial News, Stock Market Updates, Analysis, and more from the trusted sources.

CATEGORIES

  • Business
  • Cryptocurrency
  • Finance
  • Health
  • Investing
  • Markets
  • Politics
  • Stock Market
  • Technology
  • Uncategorized
  • World

LATEST UPDATES

Kenyan president plans to build huge church at his official residence

MDLZ Quantitative Stock Analysis | Nasdaq

  • Disclaimer
  • Privacy Policy
  • DMCA
  • Cookie Privacy Policy
  • Terms and Conditions
  • Contact us

Copyright © 2022 - Euro Times.
Euro Times is not responsible for the content of external sites.

No Result
View All Result
  • Home
  • Finance
  • Business
  • World
  • Politics
  • Markets
  • Stock Market
  • Cryptocurrency
  • Investing
  • Health
  • Technology

Copyright © 2022 - Euro Times.
Euro Times is not responsible for the content of external sites.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In